GPN Vaccines

Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

GPN Vaccines Pty Ltd has been established ito develop and commercialise a new broad spectrum vaccine against Streptococcus pneumoniae (the pneumococcus) - the world's foremost bacterial pathogen. S. pneumoniae causes pneumonia, bacteraemia, meningitis and otitis media and each year is responsible for 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. GPN Vaccines broad-spectrum pneumococcal vaccine was acquired from Gamma Vaccines Pty Ltd that developed this proprietary vaccine in conjunction with world-leading pneumococcal researchers at the University of Adelaide in South Australia. The award of several grants, including a $1M Development Grant from Australia's peak Medical Research Agency - the NHMRC, and a South Australian Government grant from their TechInSA Early Stage Commercialisation Fund will underpin the initial development of the Company's proprietary Gamma-PN vaccine.

Category: Health & biotech
Operational Status: Pre-launch
ASX Listing Code (if applicable):
Year of Commencement: 2017

PO Box 4435
Manuka, Canberra
ACT 2603, Australia

State: Australian Capital Territory
Overseas Operations: No
Awards won: